Lipocine Shares Are Trading Lower. The Company Reported Q3 Financial Results.

Benzinga00:51

Lipocine 3Q Research and Development Expenses $1.6M >LPCN

Dow JonesNov 7 21:09

Express News | Lipocine Q3 EPS USD -0.44

BreakingsNov 7 21:00

Press Release: Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Dow JonesNov 7 21:00

Lipocine | 10-Q: Quarterly report

SECNov 7 19:13 · Announcements

Lipocine Reports Data From Its QEEG Study Of Its Oral Brexanolone, A Proprietary Bioidentical NAS Being Developed For The Treatment Of Post-partum Depression - Filing

BenzingaOct 10 18:23